SCHEMBL4682689

SCHEMBL4682689

Cc1ccc(C(=O)NC(NC(=S)Nc2cccnc2)C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 3/20 0.67
KCNJ11 Q14654 3/20 0.67
ABCC8 Q09428 2/20 0.67
KCNJ8 Q15842 2/20 0.67
NAMPT P43490 5/20 0.60
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
ALDH1A1 P00352 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
EPHX2 P34913 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4682701 0.90 ABCC9 (0.82) ABCC9KCNJ11ABCC8KCNJ8NAMPT
SCHEMBL4678811 0.90 ABCC9 (0.82) ABCC9KCNJ11ABCC8KCNJ8NAMPT
SCHEMBL4682104 0.90 ABCC9 (0.82) ABCC9KCNJ11ABCC8KCNJ8NAMPT
SCHEMBL4681539 0.89 ABCC9 (0.82) ABCC9KCNJ11ABCC8KCNJ8NAMPT
SCHEMBL4677898 0.89 ABCC9 (0.82) ABCC9KCNJ11ABCC8KCNJ8NAMPT
SCHEMBL4682172 0.86 MAPT (0.56) ABCC9KCNJ11ABCC8KCNJ8NPC1
SCHEMBL4684022 0.85 KMT2A (0.63) ABCC9KCNJ11ABCC8KCNJ8NPC1
SCHEMBL4683467 0.83 ALDH1A1 (0.55) ABCC9KCNJ11ABCC8KCNJ8NPC1
SCHEMBL4682440 0.83 NAMPT (0.64) ABCC9KCNJ11ABCC8KCNJ8NAMPT
SCHEMBL4679575 0.82 KCNJ11 (0.53) ABCC9KCNJ11ABCC8KCNJ8RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP claimed
EP-1392655-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2004-03-03 EP claimed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US claimed
WO-2002062762-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO claimed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US claimed
EP-1392655-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2008-07-16 EP disclosed
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP disclosed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US disclosed
EP-1198456-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-24 EP disclosed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US disclosed
WO-2001009096-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2001-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028836-A1 Potassium channel openers KCNJ2, KCNJ11, KCNJ1 ABCC9 359/4885KCNJ11 2/4885ABCC8 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.